dimebolin

At this point, "there aren't enough data to even make an educated guess" about how dimebolin might turn back the symptoms of Alzheimer's, says Gandy.

Are We Taking the Wrong Approach to Curing Alzheimer’s? 2009

That produced perhaps the biggest surprise yet: in studies unveiled today at the International Conference on Alzheimer's Disease, which is going on in Vienna this week, dimebolin increased the amount of the very molecule that all the conventional wisdom about Alzheimer's holds is responsible for the disease.

Are We Taking the Wrong Approach to Curing Alzheimer’s? 2009

Perhaps Dimebon "— the trade name under which Pfizer and the biotech company Medivation are developing dimebolin —" is such a potent neuroprotectant that doubling the amyloid concentration is still completely neutralized.

Are We Taking the Wrong Approach to Curing Alzheimer’s? 2009

But he quickly became convinced that there was something to what he calls the "remarkable efficacy data," and began studying the drug, called dimebolin, himself.

Are We Taking the Wrong Approach to Curing Alzheimer’s? 2009

But when Gandy, of Mount Sinai School of Medicine in New York, and colleagues conducted a series of experiments in cells and in Alzheimer's mouse models to gauge the effect of dimebolin on beta amyloid, they found that dimebolin caused a sharp increase in beta amyloid, Gandy told the ICAD attendees. "

Are We Taking the Wrong Approach to Curing Alzheimer’s? 2009